Author:
Miranda Seixas Einloft Fernanda,Kopittke Luciane,Thais Guterres Dias Míriam,Luana Veriato Schultz Águida,Maria Dotta Renata,Maria Tannhauser Barros Helena
Abstract
AbstractIn this article we assessed the prevalence of benzodiazepine (BZD) use in women before and during imprisonment, as well as its related factors and association with symptoms of anxiety, depression, and posttraumatic stress disorder in a quantitative, cross-sectional, analytical study of regional scope. Two female prisons in the Brazilian Prison System were included. Seventy-four women participated by completing questionnaires about their sociodemographic data, BZD use and use of other substances. These questionnaires included the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Posttraumatic Stress Disorder Checklist–Civilian Version (PCL-C). Of the 46 women who reported no BZDs use before arrest, 29 (63%) began using BZDs during imprisonment (p < 0.001). Positive scores for PTSD, anxiety, and depression, as well as associations between BZD use during imprisonment and anxiety (p = 0.028), depression (p = 0.001) and comorbid anxiety and depression (p = 0.003) were found when a bivariate Poisson regression was performed. When a multivariate Poisson regression was performed for tobacco use, the PHQ-9 and GAD-7 scales, BZD use was associated with depression (p = p = 0.008), with tobacco use (p = 0.012), but not with anxiety (p = 0.325). Imprisonment increases the psychological suffering of women, consequently increasing BZD use. Nonpharmacological measures need to be considered in the health care of incarcerated women.
Funder
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. López-Muñoz, F., Álamo, C. & García-García, P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs. J. Anxiety Disord. 25, 554–562 (2011).
2. Olfson, M., King, M. & Schoenbaum, M. Benzodiazepine use in the United States. JAMA Psychiat. 72, 136 (2015).
3. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20–07–01–001, NSDUH Series H-55). https://store.samhsa.gov/ (2020).
4. Agarwal, S. D. & Landon, B. E. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open 2, e187399 (2019).
5. Bachhuber, M. A., Hennessy, S., Cunningham, C. O. & Starrels, J. L. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am. J. Public Health 106, 686–688 (2016).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献